Calcitonin-salmon: evidence, FDA status and research

It is an older hormone drug used for weak bones and bone disease. One large trial showed fewer spine breaks at only one of three doses, and the label now says the benefit is not proven.

Sold for

Calcitonin-salmon is an older bone drug, and online it is sometimes presented as a gentle alternative to bisphosphonates for osteoporosis or for bone pain after fractures.

Studies say

One large trial showed a vertebral-fracture reduction at a single dose level with an inconsistent dose response, regulators in Europe pulled the osteoporosis indication over a small cancer signal, and the FDA label now says fracture benefit is not established, so the evidence sits at B.

Why grade B. The osteoporosis use rests mainly on the PROOF trial, a five-year randomized placebo-controlled study of 1,255 postmenopausal women in which only the middle of three nasal doses reduced new vertebral fractures, with no clear dose response. The current injection label states that fracture-reduction efficacy has not been demonstrated, and a 21-trial meta-analysis cited on the label found more malignancies with calcitonin than placebo. That combination keeps the grade at B despite approval. ³⁵

FDA. Calcitonin-salmon is FDA-approved. The injection (Miacalcin) is labeled for Paget's disease of bone, hypercalcemia and postmenopausal osteoporosis; the nasal spray, now sold as a generic, is labeled only for postmenopausal osteoporosis in women more than five years past menopause when alternatives are not suitable. ⁵⁶

Written from 6 cited sources. Fact-checked 2026-10-27: 15 claims checked, 0 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Weak bones after menopause, bone disease
Can a US doctor prescribe it?: Yes, FDA approved for Paget's disease of bone, high blood calcium and bone loss after menopause.
Properly tested in people?: Partly: one 5-year trial of 1,255 women, with gaps and a small cancer warning.

Evidence checklist

Randomised controlled trial PROOF, 5-year placebo-controlled trialyes
Human study over 100 people PROOF, 1,255 postmenopausal womenyes
More than one research group Trials plus EMA and FDA reviewsyes
Clinical outcomes, not surrogate markers Vertebral fractures; only middle dose workedyes
Human safety data beyond case reports 21-trial meta-analysis found more cancersyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Calcitonin is a hormone with 32 amino acids. The thyroid gland makes it, and it lowers blood calcium. The drug copies the salmon form of the hormone. That form binds the human calcitonin receptor more strongly than human calcitonin does. It also lasts longer in the body. ²¹

The US has sold it since the 1970s as an injection. A nasal spray followed in 1995. The injection still carries the brand name Miacalcin. The nasal spray is sold as a generic. ¹⁶

How it works

Calcitonin-salmon binds calcitonin receptors on osteoclasts. These are the cells that break down bone. The drug makes them less active. Less bone breakdown means less calcium enters the blood. That is why the drug treats hypercalcemia. In Paget's disease, it slows the abnormally fast bone turnover that defines the condition. In osteoporosis, its effect on fracture risk is smaller and less steady than that of bisphosphonates. ²⁵

What human research shows

The PROOF study randomized 1,255 postmenopausal women with established osteoporosis. They got one of three nasal-spray doses or placebo for five years. Everyone also took calcium and vitamin D. The middle dose cut the risk of new spine fractures by 33% compared with placebo. The lower and higher doses did not reach significance. The authors could not fully explain this pattern. ³

The injection label sums up a meta-analysis of 21 randomized controlled trials. They tested nasal and investigational oral calcitonin-salmon. Cancers were reported in 4.1% of treated patients and 2.9% of placebo patients. Because of this, the label asks prescribers to re-check from time to time whether the patient still needs the drug. ⁵

The European Medicines Agency finished a review of calcitonin medicines in July 2012. It found a small rise in cancer risk with long-term use. It advised keeping calcitonin only for short-term use. Those uses were Paget's disease, sudden bone loss from immobilization and cancer-related hypercalcemia. It also advised pulling the nasal spray, since that was used only for osteoporosis. The FDA kept the nasal spray on the market. In 2014 it narrowed the label to women who cannot use other treatments. ⁴⁶

Study	Model	Finding
PROOF trial	Humans, n=1,255 postmenopausal women, randomized placebo-controlled, 5 years	Nasal calcitonin-salmon at the middle trial dose reduced new vertebral fractures by 33%; the other two doses did not reach significance. ³
Label meta-analysis of 21 RCTs	Humans, pooled randomized controlled trials of nasal and oral calcitonin-salmon	Malignancies in 4.1% of calcitonin-treated patients versus 2.9% on placebo. ⁵
EMA calcitonin referral	Regulatory review of trial data, 2012	Small increase in cancer risk with long-term use; nasal spray recommended for withdrawal in Europe. ⁴

Safety

The injection often causes nausea, flushing of the face or hands and reactions at the injection site. The nasal spray most often causes nose irritation, dryness or nosebleeds. Calcitonin-salmon is a foreign protein. Allergic reactions, including anaphylaxis, have been reported. The label says to consider a skin test in people who may be sensitive. Hypocalcemia can occur. ⁵⁶¹

The main long-term unknown is the cancer signal described above. The trials in the meta-analysis were not built to detect cancer. No single tumor type led. So the finding is unexplained, and no one has disproven it. ⁵⁴

Questions for your clinician

Are there bone treatments with stronger fracture data than calcitonin for me?
How should the cancer signal in the trial pooling affect how long I use it?
Why was the nasal spray withdrawn in Europe but kept in the US?

Questions people ask

Is calcitonin-salmon FDA-approved?

Yes. The injection is approved for Paget's disease, hypercalcemia and postmenopausal osteoporosis. The nasal spray is approved only for postmenopausal osteoporosis. That means women more than five years past menopause who cannot use other treatments. ⁵⁶

Why did Europe pull the nasal spray but the US did not?

In 2012 the EMA decided the cancer signal outweighed a limited fracture benefit. The nasal spray was used only for osteoporosis, so it advised withdrawal. The FDA instead narrowed the nasal spray's label in 2014. It also added the cancer data to both labels. ⁴⁶

Does calcitonin-salmon prevent fractures?

The PROOF trial found a 33% drop in new spine fractures at one dose over five years. But the dose response was uneven, and it showed no benefit for hip fractures. The current injection label says the drug has not been shown to reduce fractures. ³⁵

What is the cancer risk?

Pooled data from 21 randomized trials showed cancers in 4.1% of patients on calcitonin-salmon and 2.9% on placebo. No single cancer type explains the gap. The trials were not built to study it. So the signal is unresolved. ⁵

Citations

Drugs.com AHFS monograph: calcitonin-salmon drugs.com
DrugBank DB00017: salmon calcitonin go.drugbank.com
Chesnut 2000, Am J Med: randomized trial of nasal spray salmon calcitonin in postmenopausal osteoporosis (PROOF) doi.org
EMA referral, 2012: calcitonin-containing medicines ema.europa.eu
Miacalcin injection prescribing information drugs.com
Miacalcin nasal spray prescribing information drugs.com